-
-
-
-
-
-
-
Erasca (ERAS) Prices 86.5M Share Offering at $1.85/sh
-
-
-
-
-
-
-
Erasca, Inc (ERAS) Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors
-
-
-
-
-
-
-
Erasca (ERAS) Enters Clinical Trial Collaboration and Supply Agreement with Eli Lilly (LLY) to Evaluate ERAS-601
-
-
-
-
68,144 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

